| pubmed-article:12815171 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C0205054 | lld:lifeskim |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C0031412 | lld:lifeskim |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C0542341 | lld:lifeskim |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C1412077 | lld:lifeskim |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C0439851 | lld:lifeskim |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C0439852 | lld:lifeskim |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C1552596 | lld:lifeskim |
| pubmed-article:12815171 | lifeskim:mentions | umls-concept:C1947931 | lld:lifeskim |
| pubmed-article:12815171 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12815171 | pubmed:dateCreated | 2003-6-19 | lld:pubmed |
| pubmed-article:12815171 | pubmed:abstractText | Phenobarbital (PB) treatment impairs the biliary excretion of some organic anions. One mechanism may involve direct competition for biliary excretion by PB and/or a PB metabolite. Alternatively, PB may alter the expression and/or function of hepatic organic anion transport proteins. The role of multidrug resistance-associated protein 2 (Mrp2) in the biliary excretion of PB and metabolites was studied using isolated perfused livers (IPLs) from Wistar and Mrp2-deficient TR- rats. In normal livers, 4.19 +/- 0.53% of the PB dose was recovered in bile as PB metabolites [2.21 +/- 0.69% as 5-ethyl-5-(4-OH phenyl) barbituric acid (PBOH)-glucuronide; 1.98 +/- 0.09% as PBOH-sulfate]. In TR- livers, only PBOH-sulfate was recovered in bile (0.35 +/- 0.16% of dose) during the 2-h perfusion. Mrp2 message was increased (2.3-fold) by PB pretreatment (80 mg/kg i.p. x 4 days) but decreased to control values after a 48-h washout. Mrp2 protein was increased slightly in PB-treated livers and remained slightly elevated after a 24-h washout, but it was decreased significantly to 62 +/-7% of control values after a 48-h washout. The 120-min cumulative biliary excretion of the Mrp2 substrate 5-(and-6)-carboxy-2', 7'-dichlorofluorescein in IPLs from PB-treated rats after a 48-h washout was significantly lower than in vehicle-treated livers (66.3 +/- 9.2% versus 83.4 +/- 2.4% of the dose, respectively). These data support two mechanisms for impaired biliary excretion of some organic anions by PB treatment: 1) PBOH-glucuronide is a substrate for Mrp2 and may compete with other organic anions for biliary excretion and 2) Mrp2 protein expression and functional capacity is decreased 48 h after PB treatment. | lld:pubmed |
| pubmed-article:12815171 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12815171 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12815171 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12815171 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12815171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12815171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12815171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12815171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12815171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12815171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12815171 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12815171 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12815171 | pubmed:issn | 0026-895X | lld:pubmed |
| pubmed-article:12815171 | pubmed:author | pubmed-author:MeierPeter... | lld:pubmed |
| pubmed-article:12815171 | pubmed:author | pubmed-author:JansenPeter... | lld:pubmed |
| pubmed-article:12815171 | pubmed:author | pubmed-author:StiegerBrunoB | lld:pubmed |
| pubmed-article:12815171 | pubmed:author | pubmed-author:BrouwerKim... | lld:pubmed |
| pubmed-article:12815171 | pubmed:author | pubmed-author:ZhangPeijinP | lld:pubmed |
| pubmed-article:12815171 | pubmed:author | pubmed-author:Zamek-Gliszcz... | lld:pubmed |
| pubmed-article:12815171 | pubmed:author | pubmed-author:PatelNita JNJ | lld:pubmed |
| pubmed-article:12815171 | pubmed:author | pubmed-author:HanYong-HaeYH | lld:pubmed |
| pubmed-article:12815171 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12815171 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:12815171 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12815171 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12815171 | pubmed:pagination | 154-9 | lld:pubmed |
| pubmed-article:12815171 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:meshHeading | pubmed-meshheading:12815171... | lld:pubmed |
| pubmed-article:12815171 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12815171 | pubmed:articleTitle | Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. | lld:pubmed |
| pubmed-article:12815171 | pubmed:affiliation | Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. | lld:pubmed |
| pubmed-article:12815171 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12815171 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12815171 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12815171 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12815171 | lld:pubmed |
